Summary of the mouse models used in this study and their associated phenotypes
| Name | Genotype | N | Histological phenotype | Mets | NEPC |
|---|---|---|---|---|---|
| NPp53-SB(−) | Nkx3.1CreERT2/+; Ptenflox/flox; Trp53flox/flox; R26LSL-SB11/LSL-SB11 | 31 | Poorly differentiated adenocarcinoma with sarcomatoid features | 7/31 (22%) | 1/31 (3%) |
| NPp53-SB(+) | Nkx3.1CreERT2/+; Ptenflox/flox; Trp53flox/flox; R26LSL-SB11/LSL-SB11; T2/Onc2 | 93 | Poorly differentiated adenocarcinoma with sarcomatoid features and neuroendocrine differentiation | 57/93 (61%) | 32/84 (38%) |
| NP-SB(−) | Nkx3.1CreERT2/+; Ptenflox/flox; R26LSL-SB11/LSL-SB11 | 12 | High-grade PIN, well-differentiated adenocarcinoma | 0/12 (0%) | 0/12 (0%) |
| NP-SB(+) | Nkx3.1CreERT2/+; Ptenflox/flox; R26LSL-SB11/LSL-SB11; T2/Onc2 | 18 | High-grade PIN, well-differentiated adenocarcinoma | 0/18 (0%) | 0/18 (0%) |
| Name | Genotype | N | Histological phenotype | Mets | NEPC |
|---|---|---|---|---|---|
| 31 | Poorly differentiated adenocarcinoma with sarcomatoid features | 7/31 (22%) | 1/31 (3%) | ||
| 93 | Poorly differentiated adenocarcinoma with sarcomatoid features and neuroendocrine differentiation | 57/93 (61%) | 32/84 (38%) | ||
| 12 | High-grade PIN, well-differentiated adenocarcinoma | 0/12 (0%) | 0/12 (0%) | ||
| 18 | High-grade PIN, well-differentiated adenocarcinoma | 0/18 (0%) | 0/18 (0%) |
Mets, metastasis; NEPC, neuroendocrine prostate cancer; PIN, prostatic intraepithelial neoplasia.